VIR BIOTECHNOLOGY, INC. (VIR) News
Filter VIR News Items
VIR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VIR News Highlights
- VIR's 30 day story count now stands at 4.
- Over the past 17 days, the trend for VIR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about VIR are DE.
Latest VIR News From Around the Web
Below are the latest news stories about VIR BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate VIR as an investment opportunity.
I See a Good Trade on a $10 Biotech StockSmall biotech Vir Biotechnology, Inc. took a bit of a dump lower in July when its mid-stage flu candidate posted disappointing trial results. This is because as of the end of the third quarter, VIR Biotechnology had net cash of $1.7 billion. This means an investor is essentially getting VIR's assets for free and this can be mitigated even further via a covered call strategy. |
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value CreationSAN FRANCISCO, December 13, 2023--Vir Biotechnology makes strategic changes to focus capital allocation on programs with the highest potential for patient impact and value creation. |
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare ConferenceSAN FRANCISCO, December 06, 2023--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, will present at the J.P. Morgan 2024 42nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET. |
7 Small-Cap Stocks to Buy BEFORE the Year-End Rallyexplore and wager on these top small-cap stocks to buy, poised for significant gains in today's dynamic global economy |
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023SAN FRANCISCO, November 13, 2023--Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023 |
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023SAN FRANCISCO, November 10, 2023--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include one late-breaking poster presentation and o |
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™SAN FRANCISCO, November 08, 2023--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. This is the first time in the 29-year history of the Deloitte Technology Fast 500 program that a company has topped the list for two consecutive years. |
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call TranscriptVir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript November 2, 2023 Vir Biotechnology, Inc. misses on earnings expectations. Reported EPS is $-1.22 EPS, expectations were $-1.21. Operator: Hello, and welcome to Vir Biotechnology’s Third Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, […] |
Q3 2023 Vir Biotechnology Inc Earnings CallQ3 2023 Vir Biotechnology Inc Earnings Call |
Vir Biotechnology Inc (VIR) Reports Q3 2023 Financial ResultsCompany's revenues drop significantly from $374.6 million to $2.6 million YoY |